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Abstract—Resistance to chemotherapy and molecularly tar-
geted therapies is a major factor in limiting the effectiveness
of cancer treatment. In many cases, resistance can be linked
to genetic changes in target proteins, either pre-existing or evo-
lutionarily selected during treatment. Key to overcoming this
challenge is an understanding of the molecular determinants of
drug binding. Using multi-stage pipelines of molecular simula-
tions we can gain insights into the binding free energy and the
residence time of a ligand, which can inform both stratified and
personal treatment regimes and drug development. To support
the scalable, adaptive and automated calculation of the binding
free energy on high-performance computing resources, we intro-
duce the High-throughput Binding Affinity Calculator (HTBAC).
HTBAC uses a building block approach in order to attain both
workflow flexibility and performance. We demonstrate close to
perfect weak scaling to hundreds of concurrent multi-stage bind-
ing affinity calculation pipelines. This permits a rapid time-to-
solution that is essentially invariant of the calculation protocol,
size of candidate ligands and number of ensemble simulations.
As such, HTBAC advances the state of the art of binding affin-
ity calculations and protocols. HTBAC provides the platform to
enable scientists to study a wide range of cancer drugs and can-
didate ligands in order to support personalized clinical decision
making based on genome sequencing and drug discovery.
I. INTRODUCTION
In recent years, chemotherapy based on targeted kinase in-
hibitors (TKIs) has played an increasingly prominent role in
the treatment of cancer. TKIs have been developed to selec-
tively inhibit kinases involved in the signaling pathways that
control growth and proliferation, which often become dysregu-
lated in cancers. This targeting of specific cancers reduces the
risk of damage to healthy cells and increases treatment success.
Currently, 35 FDA-approved small molecule TKIs are in clin-
ical use, and they represent a significant fraction of the $37
billion U.S. market for oncology drugs [28], [35]. Imatinib,
the first of these of drugs, is partially credited for doubling
survivorship rates in certain cancers [35], [2].
Unfortunately, the development of resistance to these drugs
limits the amount of time that patients can derive benefits
from their treatment. Resistance to therapeutics is responsi-
ble for more than 90% of deaths in patients with metastatic
cancer [16]. While drug resistance can emerge via multiple
mechanisms, small changes to the chemical composition of the
therapeutic target (known as mutations) control treatment sen-
sitivity and drive drug resistance in many patients (see Fig. 1).
In some commonly targeted kinases such as Abl, these changes
account for as many as 90% of treatment failure [23].
There are two major strategies for countering the threat to
treatment efficacy posed by resistance: tailoring the drug reg-
imen received by a patient according to the mutations present
in their particular cancer, and developing more advanced ther-
apies that retain potency for known resistance mutations. In
both cases, future developments require insight into the molec-
ular changes produced by mutations, as well as ways to predict
their impact on drug binding on a timescale much shorter than
is typically experimentally feasible. This represents a grand
challenge for computational approaches.
The rapidly decreasing cost of next-generation sequencing
has led many cancer centers to begin deep sequencing of pa-
tient tumors to identify the genetic alterations driving individ-
ual cancers. The ultimate goal is to make individualized ther-
apeutic decisions based upon these data—an approach termed
precision cancer therapy. While several common (recurrent)
mutations have been cataloged for their ability to induce resis-
tance or for their susceptibility to particular kinase inhibitors,
the vast majority of clinically observed mutations are rare.
Essentially, this ensures that it will be impossible to make
therapeutic decisions about the majority of individual patient
tumors by using catalog-building alone.
Fortunately, concurrent improvements in computational
power and algorithm design are enabling the use of molec-
ular simulations to reliably quantify differences in binding
strength. This provides the opportunity to use advances in
molecular simulations to supplement existing inductive de-
cision support systems with deductive predictive modeling
and drug ranking [18], [24]. Where existing systems based
on statistical inference are inherently limited in their range
of applicability by the existence of data from previous sim-
ilar cases, the addition of modeling allows evidence based
decision making even in the absence of direct past experience.
The same molecular simulation technologies that can be em-
ployed to investigate the origins of drug resistance can also be
used to design new therapeutics. Creating simulation protocols
which have well defined uncertainty and produce statistically
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meaningful results represents a significant computational chal-
lenge. Furthermore, it is highly likely that differences among
investigated systems will demand different protocols as studies
progress. For example, drug design programmes often require
the rapid screening of thousands of candidate compounds to
filter out the worst binders before using more sensitive meth-
ods to refine the structure. Not all changes induced in pro-
tein shape or behavior are local to the drug binding site and,
in some cases, simulation protocols will need to adjust to ac-
count for complex interactions between drugs and their targets
within individual studies.
Recent work that used molecular simulations to provide in-
put to machine learning models [4] required simulations of 87
compounds even if they were designed merely to distinguish
the highly active from weak inhibitors of the ERK2 kinase. If
we wish to build on such studies to help inform later stages
of the drug discovery pipeline, in which much more subtle al-
terations are involved, it is likely a much larger number of
simulations will be required. This is before we begin to con-
sider the influence of mutations or the selectivity of drugs to
the more than 500 different genes in the human kinome [15].
For molecular simulations to make the necessary impact,
the dual challenge of scale (thousands of concurrent multi-
stage pipelines) and sophistication (adaptive selection of bind-
ing affinity protocols based upon statistical errors and uncer-
tainty) will need to be tackled. Tools that facilitate the scalable
and automated computation of varied binding free energy cal-
culations on high-performance computing resources are neces-
sary. To achieve that goal, we introduce the High-throughput
Binding Affinity Calculator (HTBAC). HTBAC applies recent
advances in workflow system building blocks to the accurate
calculation of binding affinities, executing hundreds of concur-
rent calculations on a leadership class machine. This permits
the rapid time-to- solution that is essentially invariant of the
size of candidate ligands as well as the type and number of
protocols concurrently employed.
In the next Section, we provide details of ensemble molec-
ular dynamics approach and its advantages over the single tra-
jectory approach. We also introduce the ESMACS and related
protocols to compute binding affinities using ensemble-based
approaches. In Section III, we discuss the computational chal-
lenges associated with the scalable execution of multiple, and
possibly concurrently executing protocols. Section IV intro-
duces RADICAL-Cybertools—a suite of building blocks to ad-
dress the challenges outlined in Section III—and describe how
they are used by HTBAC to manage the execution of binding
affinity calculations at extreme scales. Experiments to char-
acterize the performance overheads of RADICAL-Cybertools
and the weak scaling properties of the HTBAC implementation
of the ESMACS protocol on the Blue Waters supercomputer
are discussed in Section VI. We conclude with a discussion
of the impact of HTBAC, implication for binding affinity cal-
culations and near-term future work.
II. METHODOLOGY
The strength of drug binding is determined by a thermo-
dynamic property known as the binding free energy (or bind-
ing affinity). One promising technology for estimating binding
free energies and the influence of protein composition on them
is molecular dynamics (MD) [13]. Our previous work [21],
[31] has demonstrated that running multiple MD simulations
based on the same system and varying only in initial veloci-
ties offers a highly efficient method of obtaining accurate and
reproducible estimates of the binding affinity. We term this
approach ensemble molecular dynamics, “ensemble” here re-
ferring to the set of individual (replica) simulations conducted
for the same physical system. In this Section we discuss the
advantages to this approach.
A. Ensemble Molecular Dynamics Simulations
Atomistically detailed models of the drug and target protein
can be used as the starting point for MD simulations to study
the influence of mutations on drug binding. The chemistry of
the system is encoded in what is known as a potential [14].
In the parameterization of the models, each atom is assigned
a mass and a charge, with the chemical bonds between them
modeled as springs with varying stiffness. Using Newtonian
mechanics the dynamics of the protein and drug can be fol-
lowed and, using the principles of statistical mechanics, esti-
mates of thermodynamic properties obtained from simulations
of single particles.
The potentials used in the simulations are completely un-
der the control of the user. This allows the user to manipulate
the system in ways which would not be possible in exper-
iments. A particularly powerful example of this are the so
called “alchemical” simulations in which the potential used in
the simulation changes, from representing a particular start-
ing system into one describing a related target system during
execution. This allows for the calculation of free energy dif-
ferences between the two systems, such as those induced by
a protein mutation.
MD simulations can reveal how interactions change as a re-
sult of mutations, and account for the molecular basis of drug
efficacy. This understanding can form the basis for structure-
based drug design as well as helping to target existing thera-
pies based on protein composition. However, correctly captur-
ing the system behavior poses at least two major challenges:
The approximations made in the potential must be accurate
enough representations of the real system chemistry; and suf-
ficient sampling of phase space is also required.
In order for MD simulations to be used as part of clinical
decision support systems, it is necessary that results can be ob-
tained in a timely fashion. Typically, interventions are made
on a timescale of a few days or, at most, a week. The necessity
for rapid turn around times places additional demands on sim-
ulation protocols which need to be optimized to gain results
with a short turn around time. Further to the scientific and
practical considerations outlined above, it is vital that reliable
uncertainty estimates are provided alongside all quantitative
results for simulations to provide actionable predictions.
We have developed a number of free energy calculation
protocols based on the use of ensemble molecular dynamics
simulations with the aim of meeting these requirements [22],
[21], [30], [29]. Basing these computations on the direct cal-
culation of ensemble averages facilitates the determination of
statistically meaningful results along with complete control of
errors. The use of the ensemble approaches however, neces-
sitates the use of middleware to provide reliable coordination
and distribution mechanisms with low performance overheads.
B. Protocols for Binding Affinity Calculations
We have demonstrated the lack of reproducibility of sin-
gle trajectory approaches in both HIV-1 protease and MHC
systems, with calculations for the same protein-ligand combi-
nation, with identical initial structure and force field, shown to
produce binding affinities varying by up to 12 kcal mol −1 for
small ligands (flexible ligands can vary even more) [32], [21],
[34]. Indeed, our work has revealed how completely unreliable
single simulation based approaches are.
Our work using ensemble simulations have also reliably pro-
duced results in agreement with previously published experi-
mental findings [21], [31], [34], [8], [30], [29], and correctly
predicted the results of experimental studies performed by col-
leagues in collaboration [10]. While the accuracy of force
fields could be a source of error, we know from our work
to date that the very large fluctuations in trajectory-based cal-
culations account for the lion’s share of the variance (hence
also uncertainty) of the results.
We designed two free energy calculation protocols with the
demands of clinical decision support and drug design appli-
cations in mind: ESMACS (enhanced sampling of molecular
dynamics with approximation of continuum solvent) [30]
and TIES (thermodynamic integration with enhanced sam-
pling) [8]. The former protocol is based on variants of
the molecular mechanics Poisson-Boltzmann surface area
(MMPBSA) end-point method, the latter on the ‘alchemi-
cal’ thermodynamic integration (TI) approach. In both cases,
ensembles of MD simulations are employed to perform av-
eraging and to obtain tight control of error bounds in our
estimates. In addition, the ability to run replica simulations
concurrently means that, as long as sufficient compute re-
sources are available, turn around times can be significantly
reduced compared to the generation of single long trajec-
tories. The common philosophy behind the two protocols
entails similar middleware requirements: In this work we fo-
cus on the ESMACS protocol but all results are applicable
also to TIES.
Each replica within the ESMACS protocol consists of a se-
ries of simulation steps followed by post production analysis.
Generally, an ESMACS replica will contain between 3 and 12
equilibration simulation steps followed by a production MD
run, all of which are conducted in the NAMD package [20].
The first step is system minimization, the following steps in-
volve the gradual release of positional constraints upon the
structure and the heating to a physiologically realistic tempera-
ture. Upon completion of the MD simulation, free energy com-
Fig. 1. Cartoon representation of the EGFR kinase bound to the in-
hibitor AEE788 shown in chemical representation (based on PDB:2J6M). Two
residues implicated in modulating drug efficacy are highlights; in pink T790
and in orange L858. Mutations to either of these residues significantly alter
the sensitivity to TKIs.
putation (via MMPBSA and potentially normal mode analysis)
is performed using AmberTools [11], [19].
The ESMACS protocol is highly customizable. Both the
number of simulation replicas in the ensemble and the lengths
of their runs can be varied to obtain optimal performance for
any given system. Using replicas that only vary in the ini-
tial velocities assigned to the atoms of the system we have
defined a standard protocol which prescribes a 25 replica en-
semble, each run consisting of 2 ns of equilibration and 4 ns
of production simulation. Our protocol has produced bootstrap
errors of below 1.5 kcal mol−1 (despite replica values varying
by more than 10 kcal mol−1) for a varied range of systems
including small molecules bound to kinases and more flexible
peptide ligands binding to MHC proteins [32], [34], [30]. In
these systems, the error we obtained more than halves between
ensembles of 5 and 25 replicas but increases in ensemble size
have generally produced only small improvements. More gen-
erally though, there may be cases where it is important to in-
crease the sampling of phase space either through expanding
the ensemble or by considering multiple initial configurations.
The ESMACS protocol can also be extended to account for
adaptation energies involved in altering the conformation of
the protein or ligand during binding. Almost all MMPBSA
studies in the literature use the so-called 1-trajectory method,
in which the energies of protein-inhibitor complexes, receptor
proteins and ligands are extracted from the MD trajectories of
the complexes alone. The ESMACS protocol can additionally
use separate ligand and receptor trajectories to account for
adaptation energies, providing further motivation to deploy the
protocol via flexible and scalable middleware.
C. Benchmark kinase system
A common target of kinase inhibitors is the epidermal
growth factor receptor (EGFR) which regulates important
cellular processes including proliferation, differentiation and
apoptosis. EGFR is frequently over expressed in a range of
cancers, and is associated with disease progression and treat-
ment. Clinical studies have shown that EGFR mutations confer
tumor sensitivity to tyrosine kinase inhibitors in patients with
non-small-cell lung cancer (examples shown in Fig. 1) The
tyrosine kinase domain of EGFR contains 288 residues, the
full simulation system including solvent and the AEE788 in-
hibitor contains approximately 50 thousand atoms. The well
established AMBER ff99SBildn and GAFF force fields [17],
[33] were used to parameterize the system for this work.
D. Automated binding affinity calculations
The implementation of any physically realistic molecular
simulation has always been an involved and multistage pro-
cess, often requiring the scientist to overcome a large manual
overhead in the construction, preparation, and execution pro-
tocols necessary to complete a set of simulations as well as
to invoke various analysis protocols for determining desired
properties post-production.
Several tools have been been developed to automate MD
workflows for the rapid, accurate and reproducible computa-
tion of binding free energies of small molecules to their target
proteins. For example, BAC [22] is a partially automated work-
flow system which comprises (a) model building (including
incorporation of mutations into patient specific protein mod-
els), (b) running ensembles of MD simulations using a range
of free energy techniques and (c) statistical analysis. In Sec-
tion IV, we decribed how we have enhanced BAC using the
RADICAL-Cybertools to produce (HTBAC).
III. COMPUTATIONAL CHALLENGES AT EXTREME SCALE
High-performance computing (HPC) environments were de-
signed to primarily support the execution of single simulations.
Current HPC platforms enable the strong and weak scaling of
single tasks (hitherto mostly simulations), with limited soft-
ware and systems support for the concurrent execution of mul-
tiple heterogeneous tasks as part of a single application (or
workflow). As the nature of scientific inquiry and the appli-
cations to support that inquiry evolve, there is a critical need
to support the scalable and concurrent execution of a large
number of heterogeneous tasks.
Sets of tasks with dependencies that determine the order of
their execution are usually referred to as “workflows”. Often
times, the structure of the task dependencies is simple and ad-
heres to discernible patterns, even though the individual tasks
and their duration are non-trivially distinct. Put together, it
is a challenge to support the scalable execution of workflows
on HPC resources due to the existing software ecosystem and
runtime systems typically found.
Many workflow systems have emerged in response to
the aforementioned problem. Each workflow system has its
strengths and unique capability, however each system typi-
cally introduces its problems and challenges. In spite of the
many successes of workflow systems, there is a perceived high
barrier-to-entry, integration overhead and limited flexibility.
Interestingly, many commonly used workflow systems in
high-performance and distributed computing emerged from an
era when the software landscape supporting distributed com-
puting was fragile, missing features and services. Not surpris-
ingly, initial workflow systems had a monolithic design that
included the end-to-end capabilities needed to execute work-
flows on heterogeneous and distributed cyberinfrastructures.
Further, these workflow systems were typically designed by a
set of specialists to support large “big science” projects such
as those carried out at the LHC [9] or LIGO [1]. The fact
that the same workflow would be used by thousands of sci-
entists over many years justified, if not amortized, the large
overhead of integrating application workflows with monolithic
workflow systems. This influenced the design and implemen-
tation of interfaces and programming models.
However as the nature, number and usage of workflows has
evolved so have the requirements: scale remains important but
only when delivered with the ability to prototype quickly and
flexibly. Furthermore, there are also new performance require-
ments that arise from the need to support concurrent execution
of heterogeneous tasks. For example, when executing multi-
ple homogeneous pipelines of heterogeneous tasks, for rea-
sons of efficient resource utilization there is a need to ensure
that the individual pipelines have similar execution times. The
pipeline-to-pipeline fluctuation must be minimal while also
managing the task-to-task runtime fluctuation across concur-
rently executing pipelines.
Thus the flexible execution of heterogeneous ensembles MD
simulations face both system software and middleware chal-
lenges: existing system software that is typically designed to
support the execution of single large simulations on the one
hand, and workflow systems that are designed to support spe-
cific use cases or ‘locked-in’ end-to-end executions. In the
next Section, we discuss the design and implementation of
the RADICAL-Cybertools, a set of software building blocks
that can be easily composed to design, implement and execute
domain specific workflows rapidly and at scale.
IV. RADICAL-CYBERTOOLS
We have designed RADICAL-Cybertools (RCT) to be func-
tionally delineated middleware building blocks and to address
some of the challenges in developing and executing work-
flows on HPC platforms. HTBAC uses two RCT compo-
nents, mainly the Ensemble Toolkit (EnTK) and RADICAL-
Pilot (RP). EnTK provides the ability to create and execute
ensemble-based workflows/applications with complex coordi-
nation and communication but without the need for explicit
resource management. EnTK uses RP as a runtime system
which provides resource management and task execution ca-
pabilities.
RCT eschew the concept of a monolithic workflow systems
and uses “building blocks”. RCT provide scalable implemen-
tations of building blocks in Python that are used to support
dozens of scientific applications on high-performance and dis-
tributed systems [26], [3], [25], [7], [6]. In this Section we
discuss details of RP, EnTK and HTBAC, understanding how
these components have been used to support the flexible and
scalable execution of pipelines.
A. RADICAL-Pilot
The scalable execution of applications with large ensembles
of tasks is challenging. Traditionally, two methods are used to
execute multiple tasks on a resource: each task is scheduled as
an individual job, or message-passing interface (MPI) capabil-
ities are used to execute multiple tasks as part of a single job.
The former method suffers from unpredictable queue time:
each task independently awaits in the resource’s queue to be
scheduled. The latter method relies on the fault tolerance of
MPI, and is suitable to execute tasks that are homogeneous
and have no interdependencies.
The Pilot abstraction [27] solves these issues: The pilot ab-
straction: (i) uses a placeholder job without any tasks assigned
to it, so as to acquire resources via the local resource manage-
ment system (LRMS); and, (ii) decouples the initial resource
acquisition from task-to-resource assignment. Once the pilot
(container-job) is scheduled via the LRMS, it can pull compu-
tational tasks for execution. This functionality allows all the
computational tasks to be executed directly on the resources,
without being queued via the LRMS. The pilot abstraction thus
supports the requirements of task-level parallelism and high-
throughput as needed by science drivers, without affecting or
circumventing the queue policies of HPC resources.
RADICAL-Pilot is an implementation of the pilot abstrac-
tion, engineered to support scalable and efficient launching of
heterogeneous tasks across different platforms.
B. Ensemble Toolkit
An ensemble-based application is a workflow, i.e. tasks
with dependencies that determine the order of their execution.
Subsets of these tasks can be workloads, i.e., tasks whose de-
pendencies have been satisfied at a particular time and may be
executed concurrently. Ensemble-based application vary in the
type of coupling between tasks, the frequency and volume of
information exchanged between these tasks, and the executable
of each task. This type of applications requires specific coor-
dination, orchestration and execution protocols, posing both
domain-specific and engineering challenges.
Ensemble Toolkit (EnTK), the topmost layer of RCT, sim-
plifies the process of creating and executing ensemble-based
applications with complex coordination and communication
requirements. EnTK decouples the description of ensemble-
based applications from their execution by separating three
orders of concern: specification of task and resource require-
ments; resource selection and acquisition; and task execu-
tion management. Domain scientists retain full control of the
implementation of their algorithms, programming ensemble-
based applications by describing what, when and where should
be executed. EnTK uses a runtime system, like RADICAL-
Pilot, to acquire the resources needed by applications to man-
age task execution.
EnTK enables the creation of ensemble-based applications
by exposing an application programming interface (API) with
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Fig. 2. Left: Ensemble Toolkit overview showing how the abstract workflow
execution system is mapped to specific components exposed to the users and
components internal to the toolkit.
four components: Application Manager, Pipeline, Stage and
Task. Users describe ensembles in terms of pipelines, stages
and tasks, and pass this description to an instance of Applica-
tion Manager, specifying what resource to use for executing
the application (see Figure 2).
The Task component is used to encapsulate an executable
and its software environment and data dependencies. The
Stage component contains a set of tasks without mutual depen-
dencies and that can therefore be executed concurrently. The
Pipeline component is used to describe a sequence of stages,
i.e., sets of tasks that need to be executed sequentially, not
concurrently.
The use of the Task, Stage, and Pipeline components, im-
plemented as set and list data structures, avoids the need to
express explicitly relationship among tasks. These relation-
ships are insured by design, depending on the formal prop-
erties of the lists and sets used to partition tasks into stages
and group stages into pipelines. Further, EnTK enables an ex-
plicit definition of pre and post conditions on the execution
of tasks, enabling a fine grained adaptivity, both a local and
global level. Conveniently, this does not require the codifica-
tion of a directed acyclic graph (DAG), a process that imposes
a rigid representation model on the domain scientists [5].
The Application Manager component of EnTK enables
users to specify target resources for the execution of the
ensemble-based application. This includes properties like wall-
time, number of nodes and credentials for resource access.
Users can also define execution setup parameters such as the
number of processes or messaging queues that should be used
by EnTK. This allows to size and tune the performance of
EnTK, depending on the number of tasks, stages and pipelines,
but also on the resources available to the toolkit.
The Application Manager along with the WF Processor
is responsible for the transformation of the application work-
flow into workloads, i.e., set of tasks, that can be submitted to
the indicated resources for execution. Internally, the Resource
Manager and Execution Manager components enable the
acquisition of resources and the management of execution of
these workloads (see Figure 2).
V. HIGH THROUGHPUT BINDING AFFINITY CALCULATOR
Initially, we designed HTBAC to implement a single bind-
ing affinity protocol, using the EnTK programming model to
express the application logic. Here, we exclusively focus on
ESMACS to capture the workflow logic and isolate the per-
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Fig. 3. ESMACS protocol implemented as an ensemble application, encoded
using the EnTK API. A protocol represents a physical system and is encoded
as a set of independent pipelines. Each pipeline maps to a single replica.
ESMACS consists of 25 replicas. Stages within a pipeline are executed se-
quentially. Each stage contain a single task performing unique functions, as
required by the protocol. Stages S3–S6 contain molecular dynamics simula-
tion tasks executed with NAMD
formance of a single protocol instance. HTBAC has been ex-
tended as a Python library that enables the selection of multiple
protocol instances of ESMACS and TIES [12].
A simulation pipeline is a defined sequence of simulation
stages for a given physical system. In the ESMACS protocol,
these simulation pipelines are replicated, where replicas differ
only by their parameter configurations, namely initial veloci-
ties, which are randomly generated and assigned by NAMD at
the start of execution. A simulation pipeline in the ESMACS
protocol has 7 stages: the first, second and last stages perform
staging of the input/output data, the middle stages indicate
simulation tasks. A task is appended to a stage and stages
are appended to a pipeline to maintain temporal order during
execution.
Each simulation pipeline replica maps to an independent
EnTK pipeline. Each pipeline consists of a sequence of stages,
and each stage consists of a single task that performs unique
functions, including pre-processing and molecular dynamics
simulations. Fig 3 shows how pipelines, stages and tasks are
organized for the ESMACS protocol. A task is composed of
a set of attributes that define parameters like the location of
input files, the number of simulations and the MD engine(s)
used to launch those simulations.
Fig. 4 shows how the ESMACS protocol integrates with
EnTK. EnTK converts the set of pipelines into a set of tasks
called compute unit descriptions and submits them to RP. In
addition, EnTK provides methods for the user to specify a re-
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Fig. 4. ESMACS-EnTK-RP Integration. Integration between ESMACS and
EnTK. Numbers indicate the temporal sequence of execution. The database
(DB) of RADICAL-Pilot (RP) can be deployed on any host reachable from the
resources. RP pushes compute units (CU) to DB and pulls them for execution.
source request including walltime, cores, queue, and user cre-
dentials. EnTK converts this resource request into a pilot that
RP submits to a HPC machine. Once the pilot becomes ac-
tive, it pulls compute unit descriptions in bulk from a database,
executing them on the pilot resources.
VI. HTBAC EXPERIMENTS
Before embarking on a computational campaign that will
consume 150M core hours on the NCSA Blue Waters machine,
we studied the scalability of HTBAC so as to determine opti-
mal workflow sizing and resource utilization for the ESMACS
protocol. The goal is twofold: (1) understanding the invari-
ance of HTBAC execution time over the number of workflow
pipelines executed; and (2) studying how the performance of
EnTK and RP varies in relation to the size of workflow.
A. Experiment Design
We designed two experiments to measure HTBAC, EnTK
and RP weak scalability when executing an increasing number
of concurrent pipelines. According to the use case described in
Section V, each pipeline consists of seven stages, each stage
with a single task. EnTK manages the queuing of the tasks
in accordance with the order and concurrency mandated by
stages and pipelines: For each pipeline, each stage is executed
sequentially while pipelines are executed concurrently.
Experiment 1 measures the baseline behavior of EnTK and
RP with the workflow of the ESMACS protocol and a null
workload (/bin/sleep 0). The goal is to isolate the overheads
of EnTK and RP from the specifics of the executables of the
workflow and the overheads of the resources. The null work-
load does not require data staging, I/O on both memory and
disk, or communication over network.
Experiment 2 replicates the design of Experiment 1 but it
executes the workflow of the ESMACS protocol with the ac-
tual simulation and data for the EGFR kinase workload. The
comparison between the two experiments enables performance
analysis of EnTK and RP to understand whether and how the
size of the executed workflow affects its overheads. Further,
Experiment 2 shows also whether HTBAC execution time is
sensitive to the number of concurrent pipelines executed.
Both experiments measure the weak scalability of HTBAC,
EnTK and RP. This means that the ratio between the number
of pipelines and cores is kept constant by design. While an
investigation of strong scalability would contribute to a better
understanding of the behavior of HTBAC, EnTK and RP, it is
of limited interest for the current use case. The driving goal
of HTBAC is to increase throughput by a means of concur-
rency of pipelines, not in the number of sequential executions
per core. This is a driving motivation to target large HPC ma-
chines instead of so-called high-throughput computing (HTC)
infrastructures.
B. Experiment Setup
We perform both Experiment 1 and 2 on NCSA’s Blue
Waters—a 13.3 petaFLOPS Cray, with 32 Interlago cores/50
GB RAM per node, Cray Gemini, Lustre shared file system.
Currently, we exclusively use CPUs on Blue Waters as GPUs
are not required by our use case. RCT support the use of both
type of architectures and we previously benchmarked the use
of GPUs.
We perform our experiments from a virtual machine hosted
in Europe. This helps to simulate the conditions in which
the experimental campaign will be performed by the research
group at UCL. This is relevant because, as most HPC re-
sources, Blue Waters does not allow for executing applications
on the login node of the cluster. To this end, RCTs support
gsissh for X509 authentication and authorization.
Table I shows the setup for Experiment 1 and 2. The ES-
MACS protocol is executed with up to 25 concurrent but in-
dependent pipelines and therefore their concurrent execution
does not entail communication overhead. Further, the EGFR
kinase studies can benefit from greater concurrency because
potential HTBAC users may wish to extend their protocols
beyond the current scale of ESMACS. Consistently, our ex-
periments push the boundaries of current scale by executing
8, 16, 32, 64 and 128 concurrent pipelines.
EnTK uses RP to acquire resources via a single pilot. The
size of the pilot is contingent upon characterization of perfor-
mance, in this case, weak scalability. Accordingly, we request
the maximum number of cores required by the workload as
the number of cores in a pilot. We use between 64 and 1024
cores in Experiment 2 as the NAMD executable used in stages
3, 4, 5, and 6 requires 8 cores. Stages 1, 2 and 7 require in-
stead 1 core. The null workload of Experiment 1 requires only
1 core per stage but we request the same number of cores as
for Experiment 2 to be able to compare the overheads of both
EnTK and RP across experiments.
All experiments use EnTK version 0.4.7 and RP version
0.42. The MD engine used is NAMD-MPI. The equilibration
tasks of stage 4 and 6 are assigned 5000 timesteps while the
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Fig. 5. Overheads of Ensemble Toolkit (EnTK) and RADICAL-Pilot (RP)
when executing HTBAC using a null workload. We plot the baseline EnTK/RP
overheads without the application workload across two trials per pipeline
configuration.
task of stage 5 requires 55000 timesteps. We ran two trials of
both the null and MD workload at each pipeline configurations.
C. Results
First we characterize the overhead of EnTK and RP in the
null workload, where we isolate the overhead introduced by
the two systems (Figure 5). We see a (slightly) superliner in-
crease of EnTK overhead, between 0.1 and 1.8 seconds. This
overhead depends on the number of tasks that need to be trans-
lated in-memory from a Python object to a CU description. As
such, it is expected to grow proportionally to the number of
tasks, barring some competition of resources.
RP overhead is also, on average, superlinear but with a
much greater variance. This variance is due to mainly two
factors: Network latency and filesystem latency on the HPC re-
source. EnTK submits CU descriptions to the MongoDB used
by RP, and the RP pilot pulls these descriptions from the same
database. As described in Section VI-B, this pull operation oc-
curs over a wide area network, introducing varying amounts
of latency. Further, RP writes and reads the CU descriptions
multiple times to and from the shared filesystem of the HPC
machine. Together, these two factors introduce delays in the
scheduling of the CUs.
When the workload includes the EGFR kinase, we see (Fig-
ure 6) that the RP overhead becomes on average less than
10% of the average total execution time (TTX), defined as
TTX = TTC − Tq where TTC is time-to-completion and
Tq is time spent queuing on the HPC machine. We further
break down TTX into the time-to-completion per stage, where
stages 1,2, and 7 perform file movements, while stages 3,4,5,
and 6 execute NAMD tasks. At this level, we notice that the
time-to-completion of the NAMD stages are essentially in-
variant across pipelines of different size while file movement
stages exhibit linearly increasing behavior. In addition, when
accounting for variance, RP overheads also show linear weak
scaling behavior. As expected, EnTK overhead remains super-
linear and comparable to the one measured in Experiment 1.
This is because in both experiments EnTK overhead depends
on the number of tasks translated to CU descriptions.
TABLE I
EXPERIMENT 1 EXECUTES THE 7 STAGES OF THE ESMACS PROTOCOL WITH A NULL WORKLOAD; EXPERIMENT 2 USES THE ACTUAL MD WORKLOAD
OF THE ESMACS PROTOCOL. ESMACS PROTOCOL WITH EGFR KINASE WORKLOAD: (1) UNTAR CONFIGURATION FILES; (2) PREPREP; (3) MINIMIZE
WITH DECREASING RESTRAINTS; (4) EQUILIBRATION: NVT SIMULATION AT 50K, WITH RESTRAINTS; (5) EQUILIBRATION: NPT SIMULATION AT 300K,
WITH DECREASING RESTRAINTS; (6) EQUILIBRATION: NPT AT 300K, NO CONSTRAINTS; (7) TARBALL OUTPUT FILES.
Experiment ID Protocol Workload # Trials # Pipelines # Stages # Tasks # Cores per pilot
1 ESMACS Null workload 2 8, 16, 32, 64, 128 7 7 64, 128, 256, 512, 1024
2 ESMACS EGFR kinase Workload 2 8, 16, 32, 64, 128 7 7 64, 128, 256, 512, 1024
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Fig. 6. Similar EnTK/RP overhead behavior as with the null workload with
higher values as the number of pipelines increases. We show a breakdown of
TTX of each stage (Stage 1–7). Across pipeline configurations, TTX and RP
overheads (accounting for the error bars) show weak scaling performance.
Experiments 1 and 2 show how the overheads of both EnTK
and RP tend to be invariant across type of workload executed.
Their scaling behavior and, to some approximation, their ab-
solute values are comparable between Figure 5 and 6. This is
relevant because it shows that the systems used to coordinate
and execute the ESMACS protocol add a constant and com-
paratively not relevant overhead to the execution of NAMD.
VII. DISCUSSION AND CONCLUSION
It is necessary to move beyond the prevailing paradigm of
running individual MD simulations, which provide irrepro-
ducible results and cannot provide meaningful error bars [8].
Further, the ability to flexibly scale and adapt ensemble-based
protocols to the systems of interest is vital to produce reli-
able and accurate results on timescales which make it viable
to influence real world decision making. To meet these goals,
we are designing and developing the high-throughput binding
affinity calculator (HTBAC).
HTBAC employs the RADICAL-Cybertools to build
ensemble-based applications for executing protocols like ES-
MACS at scale. We show how the implementation of the
ESMACS protocol scales almost perfectly to hundreds of
concurrent pipelines of binding affinity calculations on Blue
Waters. This permits a time-to-solution that is essentially in-
variant of the size of candidate ligands, as well as the type
and number of protocols concurrently employed.
The use of software implementing well-defined abstractions
like that of “building blocks”, future proofs users of HTBAC to
evolving hardware platforms, while providing immediate ben-
efits of scale and support for a range of different application
workflows. Thus, HTBAC represents an important advance to-
wards the use of molecular dynamics based free energy calcu-
lations to the point where they can produce actionable results
both in the clinic and industrial drug discovery.
In the short term, the development of HTBAC will allow a
significant increase in the size of study. Much of the literature
on MD-based free energy calculations is limited to a few tens
of systems, usually of similar drugs bound to the same protein
target. By facilitating investigations of much larger datasets,
HTBAC also provides a step towards tackling grand challenges
in drug design and precision medicine, where it is necessary
to understand the influences on binding strength for hundreds
or thousands of drug-protein variant combinations. Only in
aiming to meet this ambitious goals we will be able to reveal
the limits of existing simulation technology and the potentials
used to approximate the chemistry of the real systems.
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